Atypical teratoid/rhabdoid tumor

Changed by Jeremy Jones, 19 Aug 2018

Updates to Article Attributes

Body was changed:

Atypical teratoid/rhabdoid tumours (AT/RT) are an uncommon WHO Grade IV tumour, which in the vast majority of cases occurs in young children less than two years of age. It most frequently presents as a posterior fossa mass. AT/RT often resembles medulloblastoma by imaging and even H&E microscopy, and the diagnosis requires cytogenetic analysis of the tissue.

Epidemiology

They present in young children (median age is less than 2-3 years 2), whereas medulloblastomas typically occur in mid-childhood (median age 6 years).

Pathology

Microscopic features

Rhabdoid cells are the hallmark of AT/RT, but only comprise a fraction of the tumour. Other portions of the tumour are indistinguishable on imaging and histology from a medulloblastoma or supratentorial primitive neuroectodermalembryonal tumour (PNETwith multilayered rosettes).

According to 2016 WHO classification scheme, a diagnosis of AT/RT requires confirmation of specific genetic aberration (loss of INI1 tumour suppressor gene on chromosome 22 or BRG1 gene); otherwise, a descriptive diagnosis of CNS embryonal tumour with rhabdoid features is used 8,10.

Immunophenotype
  • EMA: positive
  • vimentin: positive
  • smooth muscle actin: positive

Radiographic features

Atypical teratoid/rhabdoid tumour are usually large and very heterogeneous masses. They may be difficult to distinguish from a PNET by imaging.

Location
  • infratentorial: ~50%
    • cerebellum (most common)
    • brainstem
  • supratentorial
CT
  • often isodense to grey matter
  • may demonstrate heterogeneous enhancement
  • calcification is common
  • may show associated obstructive hydrocephalus
MRI

Can show necrosis, multiple foci of cyst formation and sometimes haemorrhage:

  • T1: iso- to slightly hyperintense to grey matter (haemorrhagic areas can be more hyperintense)
  • T2: generally hyperintense (haemorrhagic areas can be hypointense)
  • T1 C+ (Gd): heterogeneous enhancement
  • MR spectroscopy
    • Cho: elevated
    • NAA: decreased
  • DWI
    • almost all restrict diffusion

Leptomeningeal seeding has been described in up to 15-30% of cases and so post-contrast imaging of the entire neuroaxis should be considered in suspected AT/RTs.

Treatment and prognosis

Surgery with debulking can be offered in some cases. Tumours can demonstrate leptomeningeal dissemination. Clinically AT/RTs have much poorer prognosis than medulloblastomas, with little if any response to chemotherapy and death usually occurring within a year of diagnosis. 

History and etymology

Primary CNS rhabdoid tumour was first identified as a unique entity in the mid/late 1980's. Prior to this, these tumours were likely misdiagnosed as primitive neuroectodermal tumour/medulloblastoma, as they are relatively similar in microscopic appearance 12. Early reports variably used the term malignant rhabdoid tumour.

Differential diagnosis

Imaging differential considerations include:

  • -<p><strong>Atypical teratoid/rhabdoid tumours</strong> <strong>(AT/RT)</strong> are an uncommon <a href="/articles/who-classification-of-cns-tumours-1">WHO Grade IV</a> tumour, which in the vast majority of cases occurs in young children less than two years of age. It most frequently presents as a <a href="/articles/posterior-fossa-tumours">posterior fossa mass</a>. AT/RT often resembles <a title="Medulloblastoma" href="/articles/medulloblastoma">medulloblastoma</a> by imaging and even H&amp;E microscopy, and the diagnosis requires cytogenetic analysis of the tissue.</p><h4>Epidemiology</h4><p>They present in young children (median age is less than 2-3 years <sup>2</sup>), whereas medulloblastomas typically occur in mid-childhood (median age 6 years).</p><h4>Pathology</h4><h5>Microscopic features</h5><p>Rhabdoid cells are the hallmark of AT/RT, but only comprise a fraction of the tumour. Other portions of the tumour are indistinguishable on imaging and histology from a medulloblastoma or supratentorial primitive neuroectodermal tumour (<a href="/articles/primitive-neuroectodermal-tumour-of-the-cns">PNET</a>).</p><p>According to 2016 WHO classification scheme, a diagnosis of AT/RT requires confirmation of specific genetic aberration (loss of INI1 tumour suppressor gene on chromosome 22 or BRG1 gene); otherwise, a descriptive diagnosis of <strong>CNS </strong><strong>embryonal</strong><strong> tumour with rhabdoid features </strong>is used <sup>8,10</sup>.</p><h5>Immunophenotype</h5><ul>
  • +<p><strong>Atypical teratoid/rhabdoid tumours</strong> <strong>(AT/RT)</strong> are an uncommon <a href="/articles/who-classification-of-cns-tumours-1">WHO Grade IV</a> tumour, which in the vast majority of cases occurs in young children less than two years of age. It most frequently presents as a <a href="/articles/posterior-fossa-tumours">posterior fossa mass</a>. AT/RT often resembles <a href="/articles/medulloblastoma">medulloblastoma</a> by imaging and even H&amp;E microscopy, and the diagnosis requires cytogenetic analysis of the tissue.</p><h4>Epidemiology</h4><p>They present in young children (median age is less than 2-3 years <sup>2</sup>), whereas medulloblastomas typically occur in mid-childhood (median age 6 years).</p><h4>Pathology</h4><h5>Microscopic features</h5><p>Rhabdoid cells are the hallmark of AT/RT, but only comprise a fraction of the tumour. Other portions of the tumour are indistinguishable on imaging and histology from a medulloblastoma or <a title="Embryonal tumours with multilayered rosettes (ETMR)" href="/articles/embryonal-tumours-with-multilayered-rosettes-etmr">embryonal</a><a title="Embryonal tumours with multilayered rosettes (ETMR)" href="/articles/embryonal-tumours-with-multilayered-rosettes-etmr"> tumour with multilayered rosettes</a>.</p><p>According to 2016 WHO classification scheme, a diagnosis of AT/RT requires confirmation of specific genetic aberration (loss of INI1 tumour suppressor gene on chromosome 22 or BRG1 gene); otherwise, a descriptive diagnosis of <strong>CNS </strong><strong>embryonal</strong><strong> tumour with rhabdoid features </strong>is used <sup>8,10</sup>.</p><h5>Immunophenotype</h5><ul>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.